Hemophilia B Market Size, Share and Growth Outlook, 2026

Hemophilia B Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Hemophilia B Market size is forecast to increase from $5.58 Billion in 2026 to $9.88 Billion in 2034 at a CAGR of 7.4% between 2026 and 2034.

The Hemophilia B market report provides detailed analysis and outlook of Hemophilia B segments including By Product Type (Factor IX Replacement Therapy, Extended Half-Life, Gene Therapy, Non-Factor Therapies ), By Severity (Severe Hemophilia B, Moderate Hemophilia B, Mild Hemophilia B), By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By End-User (Hospitals & Specialty Clinics, Hemophilia Treatment Centers (HTCs), Homecare Settings) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Hemophilia B Industry Overview

Commercial Gene Therapy Implementation Advances Hemophilia B Care

The hemophilia B industry is entering a new phase of clinical practice as gene therapies transition from controlled clinical trials into routine healthcare settings. A significant milestone was achieved through the successful commercial administration of HEMGENIX® (etranacogene dezaparvovec) by the Gulf States Hemophilia and Thrombophilia Center. These treatments represent the first documented series of commercial gene therapy infusions for adult hemophilia B patients outside traditional clinical research environments. The implementation process established standardized protocols for patient identification, treatment logistics, reimbursement pathways, administrative coordination, and long-term liver function monitoring. The successful integration of gene therapy into real-world clinical practice demonstrates the increasing maturity of advanced genetic medicine and highlights the healthcare infrastructure developments required to support widespread adoption of transformative therapies for inherited bleeding disorders.

Regional Regulatory Approvals Expand Access to Gene Therapy Solutions

Regulatory progress continues to accelerate the availability of advanced treatment options within the hemophilia B market. The Pharmaceutical Administration Bureau of the Macao Special Administrative Region granted approval for BBM-H901, also known as Dalnacogene Ponparvovec Injection, for adult patients with hemophilia B. The therapy had previously achieved a historic milestone as the first domestically developed gene therapy approved in mainland China. BBM-H901 utilizes a highly active FIX-Padua variant controlled by a liver-specific promoter to enhance factor IX expression and improve coagulation function. Following regulatory authorization, commercialization efforts are being expanded through a collaborative accessibility framework involving Takeda China. These developments reflect growing international acceptance of gene therapy technologies and demonstrate the increasing role of regional regulatory agencies in supporting innovation within the treatment landscape for hereditary bleeding disorders.

Next-Generation Vector Technologies Drive Future Pipeline Development

Research and development activity remains strong within the hemophilia B industry as companies seek to enhance gene therapy performance through improved vector engineering. Advanced biochemical evaluations of liver-directed adeno-associated virus platforms have highlighted the emergence of SPK-8011QQ, a next-generation gene therapy candidate developed by Spark Therapeutics, a Roche subsidiary. Preclinical studies conducted in laboratory and animal models demonstrated improved factor IX expression levels and enhanced hemostatic activity compared with earlier vector generations. These encouraging findings have supported strategic plans to advance the program into multicenter Phase IIb clinical studies. The continued evolution of vector technology reflects the industry's focus on maximizing therapeutic durability, improving coagulation outcomes, and expanding the potential benefits of gene therapy for patients with hemophilia B. As innovation progresses, next-generation genetic medicines are expected to remain central to future treatment development efforts across the bleeding disorders sector.

Hemophilia B Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Hemophilia B market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- CSL Behring, Pfizer Inc., Sanofi S.A., uniQure N.V., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Grifols, S.A., Octapharma AG, Biotest AG, Kedrion Biopharma. The Hemophilia B market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Hemophilia B industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Hemophilia B Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Hemophilia B companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Hemophilia B markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Hemophilia B Market Competitive Benchmarking and Company Analysis

Leading companies in Hemophilia B industry include- CSL Behring, Pfizer Inc., Sanofi S.A., uniQure N.V., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Grifols, S.A., Octapharma AG, Biotest AG, Kedrion Biopharma. The Hemophilia B market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Hemophilia B Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Hemophilia B market remains one of the strongest-performing segments in the country.
The US Hemophilia B Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Hemophilia B market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Hemophilia B industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Hemophilia B markets

Canada's strong Hemophilia B sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Hemophilia B market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Hemophilia B Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Hemophilia B market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Hemophilia B population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Hemophilia B industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Hemophilia B market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Hemophilia B sales through 2034

France Hemophilia B companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Hemophilia B Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Hemophilia B distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Hemophilia B Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Hemophilia B market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Hemophilia B industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Hemophilia B industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Hemophilia B Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Hemophilia B market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Hemophilia B market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Hemophilia B Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Hemophilia B Market Segmentation

By Product Type
Factor IX Replacement Therapy
Extended Half-Life
Gene Therapy
Non-Factor Therapies
By Severity
Severe Hemophilia B
Moderate Hemophilia B
Mild Hemophilia B
By Route of Administration
Intravenous (IV)
Subcutaneous (SC)
By End-User
Hospitals & Specialty Clinics
Hemophilia Treatment Centers (HTCs)
Homecare Settings

Top Companies in Hemophilia B Industry

CSL Behring
Pfizer Inc.
Sanofi S.A.
uniQure N.V.
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Grifols, S.A.
Octapharma AG
Biotest AG
Kedrion Biopharma

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025